Polyphor In Peril After Breast Cancer Drug Failure
Shares Crash On Balixafortide Setback
Polyphor has seen its remaining asset balixafortide bite the dust and "a strategic assessment regarding the future of the company" is underway for a firm that not so long ago was seen as a rising star in the Swiss biotech sector.
You may also be interested in...
Future For Spexis Looks Far From Secure
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
Road Ahead Unclear For Polyphor’s Intravenous Murepavadin
The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.
Polyphor's Stock Slides As Murepavadin Trials Are Halted
The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.